Home / ASCO Direct Highlights / Cancer Genomics and Molecular Diagnostics Online Course

Cancer Genomics and Molecular Diagnostics Online Course

ASCO® DIRECT Highlights  2019:  Cancer Genomics and Molecular Diagnostics

Target Audience

The primary target audience for this meeting comprise the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; pharmacists; physician assistants; and other allied health care professionals.


ASCO DIRECT™ HIGHLIGHTS condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting. The abstracts chosen for presentation and discussion reflect state-of-the-art developments and recent advances in oncology that will directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment. Expert faculty place abstract findings into clinical context and discuss how the results may change the current standard of care.


At the end of this educational activity, participants should be able to:

  • Review highlights from studies focused on cancer genomics presented at the 2019 ASCO® Annual Meeting
  • Identify emerging trends and strategies in cancer genomics and molecular diagnostics that can be used to monitor clinical efficacy of treatment and improve patient outcomes 


Jeffrey Gregg, MD
Senior Director, Clinical Pathology
Director, Molecular Diagnostics
Professor of Pathology
Department of Pathology and Laboratory Medicine
University of California, Davis Medical Center
Scientific Advisor, Liquid Biopsy
Foundation Medicine, Inc.

Access Course
Link Coming Soon


This activity is supported in part by educational grants from Astellas and Seattle Genetics, Amgen, Celgene Corporation, Daiichi Sankyo, Inc., Lilly, Merck & Co., Inc. and TESARO, Inc.